Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy

Fig. 2

Genetic alterations used as predictive biomarkers for APL patients. a Chromosomal translocations between RARA and several fusion partners playing an important role in maintaining resistance/sensitivity of APL patients to retinoids [122]. b Breakpoint cluster regions (bcr) in PML gene resulting in alternative splicing and different therapeutic response to ATRA in APL patients. E5(−)E6(−) isoform of L-type fusion transcript with exons 5 and 6 deleted is associated with the ATRA-resistant phenotype

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us